Repository logo
 

Development of Antibody-Directed Therapies: Quo Vadis?

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Rodrigues, Tiago 
Bernardes, Gonçalo JL  ORCID logo  https://orcid.org/0000-0001-6594-8917

Abstract

Less is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.

Description

Keywords

anti-tumor agents, antibody-drug conjugates, bioconjugation, drug delivery, linkers, Animals, Breast Neoplasms, Bystander Effect, Cell Line, Tumor, Drug Liberation, Female, Humans, Immunoconjugates, Mice, Neoplasms, Oligopeptides, Transplantation, Heterologous

Journal Title

Angew Chem Int Ed Engl

Conference Name

Journal ISSN

1433-7851
1521-3773

Volume Title

57

Publisher

Wiley
Sponsorship
Engineering and Physical Sciences Research Council (EP/M003647/1)
The Royal Society (uf110046)
European Research Council (676832)
European Commission (EC) (852985)